Aydan Eroglu, Serkan Akbulut, Sancar Bayar, Gokhan Avsar, Riza Deryol

Analysis of stereotactic biopsies for nonpalpable BIRADS 4 breast lesions: Evaluation of predictors for malignancy

Aim: This study aims to determine the malignancy rates of nonpalpable BIRADS 4 breast lesions excised by stereotactic biopsy, the re-excision rates of malignant lesions detected by stereotactic biopsy and to evaluate the factors affecting malignancy rates in these lesions. Materials and Methods: Medical records of female patients admitted to the surgical oncology outpatient clinic between 2012 and 2017 with nonpalpable (

PDF

___

1. Schonberg MA. Overutilization of Breast Cancer Screening in the US: Awareness of a Growing Problem. J Gen Intern Med 2018;33:238-40.
2. Niell BL, Freer PE, Weinfurtner RJ, et al. Screening for Breast Cancer. Radiol Clin North Am 2017;55:1145- 62.
3. Cakmak GK, Emiroglu S, Sezer A, et al. Surgical Trends in Breast Cancer in Turkey: An Increase in BreastConserving Surgery. JCO Glob Oncol 2020;6:285-92.
4. Isik A, Grassi A, Soran A. Positive Axilla in Breast Cancer; Clinical Practice in 2018. Eur J Breast Health 2018;14:134-5.
5. Shea B, Boyan WP Jr, Kamrani K, et al. Let us cut to the core: is core biopsy enough for subcentimeter breast cancer? J Surg Res 2017;216:30-4.
6. Calhoun BC. Core Needle Biopsy of the Breast: An Evaluation of Contemporary Data. Surg Pathol Clin 2018;11:1-16.
7. Iflazoglu N, Ureyen O, Atahan MK, et al. A Retrospective Comparative Study of Image-Guided Excisional Biopsy in High-Risk Non-Palpable Breast Lesions: Predictive Factors for Malignancy. J Breast Health 2015;11:132-7.
8. Madeley C, Kessell M, Madeley C, et al. A comparison of stereotactic and tomosynthesis-guided localisation of impalpable breast lesions. J Med Radiat Sci 2019;66:170-6.
9. Godfrey SE. Is fibrocystic disease of the breast precancerous? Arch Pathol Lab Med 1986;110:991.
10. Sen LQC, Huang ML, Leung JWT, et al. Malignancy rates of stereotactic biopsies of two or more distinct sites of suspicious calcifications in women without known breast cancer. Clin Imaging 2019;58:156-60.
11. Grimm LJ, Johnson DY, Johnson KS, et al. Suspicious breast calcifications undergoing stereotactic biopsy in women ages 70 and over: Breast cancer incidence by BI-RADS descriptors. Eur Radiol 2017;27:2275-81.
12. Lee AHS. Why is carcinoma of the breast more frequent in the upper outer quadrant? A case series based on needle core biopsy diagnoses. Breast 2005;14:151-2.
13. Han Y, Moore JX, Langston M, et al. Do breast quadrants explain racial disparities in breast cancer outcomes? Cancer Causes Control 2019;30:1171-82.
14. Barentsz MW, Postma EL, van Dalen T, et al. Prediction of positive resection margins in patients with nonpalpable breast cancer. Eur J Surg Oncol 2015;41:106- 12.
15. Tsai HY, Chao MF, Ou-Yang F, et al. Accuracy and outcomes of stereotactic vacuum-assisted breast biopsy for diagnosis and management of nonpalpable breast lesions. Kaohsiung J Med Sci 2019;35:640-5.
16. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001;218:497-502.
17. Bundred SM, Maxwell AJ, Morris J, et al. Randomized controlled trial of stereotactic 11-G vacuum-assisted core biopsy for the diagnosis and management of mammographic microcalcification. Br J Radiol 2016;89:20150504.
18. Sickles EA, D’Orsi CJ, Bassett LW, et al. ACR BI-RADS® Mammography. In: Reston VA, ed. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. American College of Radiology 2013. p. 37-78.
19. Kim SY, Kim HY, Kim EK, et al. Evaluation of malignancy risk stratification of microcalcifications detected on mammography: a study based on the 5th edition of BI-RADS. Ann Surg Oncol 2015;22:2895-901.